Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Carcinoma, Ovarian Epithelial 1

Interventions

Dexamethasone 46Lenalidomide 30Bortezomib 24daratumumab 23pomalidomide 20Cyclophosphamide 16carfilzomib 15Specimen Handling 14Biopsy 14Calcium Dobesilate 12isatuximab 11Magnetic Resonance Spectroscopy 10talquetamab 9Melphalan 8iberdomide 7fludarabine 7belantamab mafodotin 6tocilizumab 5selinexor 5dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5X-Rays 5fludarabine phosphate 4elotuzumab 4Sirolimus 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Clarithromycin × 30 days × Clear all
NCT04302324 2026-05-20

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
11 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡